Norprolac (Quinagolide)

Quinagolide, the active ingredient in Norprolac, is a dopamine agonist presented as an oral tablet for oral use. It reduces excess prolactin secretion and is typically prescribed by endocrinologists for treatment. GNH USA supplies Norprolac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quinagolide acts on the dopaminergic pathway to lower prolactin levels and is indicated for the following conditions: - Hyperprolactinemia: normalizes serum prolactin concentrations, alleviating associated symptoms. - Prolactinoma: reduces tumor size and prolactin output in patients with pituitary prolactin‑secreting adenomas. - Galactorrhea: suppresses inappropriate milk production unrelated to pregnancy or lactation.

Quinagolide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Dizziness - Fatigue

Serious or Rare Side Effects: - Valvular heart disease - Pulmonary hypertension - Severe depression - Cardiac arrhythmia

When prescribing Quinagolide, several safety considerations should be observed. - Assess baseline prolactin levels: confirm hyperprolactinemia before initiating therapy. - Monitor cardiac function: periodic echocardiography is advised due to potential valvular effects. - Evaluate psychiatric status: watch for emergence of depression or psychotic symptoms. - Avoid use in patients with uncontrolled hypertension: quinagolide may exacerbate blood pressure. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Quinagolide can interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Concomitant use with ergot‑derived dopamine agonists: additive risk of cardiac valvulopathy. - Combination with potent CYP3A4 inhibitors (e.g., ketoconazole): may increase quinagolide plasma levels. - Co‑administration with serotonergic agents (e.g., SSRIs): heightened risk of serotonin syndrome. - Use with antihypertensive agents: may cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely): - Concurrent use with other dopamine agonists (e.g., cabergoline): may amplify dopaminergic effects. - Co‑administration with antipsychotics that block D2 receptors: may reduce therapeutic efficacy.